Plasma chromogranin A. Initial studies in human hypertension

Area of Science:

• Endocrinology
• Hypertension Research
• Neuroscience

Background:

• Chromogranin A (CgA) is a key soluble protein in catecholamine storage vesicles.
• It is coreleased with catecholamines during exocytosis and circulates in human plasma.
• Plasma CgA may serve as an indicator of sympathoadrenal activity.

Purpose of the Study:

• To investigate plasma chromogranin A concentrations in normotensive individuals, essential hypertension patients, and secondary hypertension patients.
• To explore the relationship between plasma CgA and sympathoadrenal activity in hypertension.
• To assess the effect of sympathetic outflow suppression on plasma CgA levels.

Main Methods:

• Measurement of plasma chromogranin A concentrations in different subject groups.
• Comparison of CgA levels between normotensive controls and hypertensive patients (essential, renal parenchymal disease, pheochromocytoma).
• Administration of guanabenz to essential hypertensive patients to assess changes in plasma CgA and blood pressure.

Main Results:

• Plasma CgA was significantly higher in essential hypertension patients compared to normal controls.
• Elevated plasma CgA levels were also observed in hypertension secondary to renal parenchymal disease and pheochromocytoma.
• Short-term sympathetic blockade with guanabenz reduced plasma CgA in essential hypertensive subjects.

Conclusions:

• Plasma chromogranin A levels are influenced by neural control.
• Elevated plasma CgA in essential hypertension suggests increased exocytotic sympathoadrenal activity.
• Plasma CgA shows potential as a biomarker for sympathoadrenal activity in hypertensive disorders.